Figma Shares Indicated To Open $105/$110
CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group, announced that its CEO, Greg Siokas, has significantly increased his ownership in the company by purchasing 1,466,764 common shares, totaling $526,000. These transactions occurred over a four-day period from April 21 to April 24, 2025. The purchases come as the stock trades at $0.42, significantly below its 52-week high of $1.58. According to InvestingPro analysis, COSM is currently undervalued based on its Fair Value metrics.
Following these acquisitions, Siokas now beneficially owns 5,582,066 common shares of Cosmos Health. Siokas expressed his commitment to the company, highlighting his investment of over $1.3 million in the past five months, which has increased his share ownership by more than 2.7 million. He underscored his confidence in the company’s value creation for shareholders and his excitement for future opportunities. InvestingPro data shows the company has faced challenges, with a -40% one-year return, though analysts project profitability for 2025.
Cosmos Health, incorporated in 2009 in Nevada, operates as a vertically integrated healthcare group with a portfolio that includes proprietary pharmaceutical and nutraceutical brands such as Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept®, and C-Scrub®. Its subsidiary, Cana Laboratories S.A., manufactures a range of products within the European Union, adhering to European Good Manufacturing Practices and certified by the European Medicines Agency. The company generated revenue of $54.43 million in the last twelve months, though InvestingPro identifies challenges with its gross profit margins at 7.92%.
The company also distributes pharmaceuticals and parapharmaceuticals to retail pharmacies and wholesale distributors in Greece and the UK. Cosmos Health has established research and development partnerships to address significant health disorders and has ventured into the telehealth space through the acquisition of ZipDoctor, Inc.
This announcement is based on a press release statement, which also includes forward-looking statements regarding the company’s future plans and potential. These forward-looking statements are subject to various risks and uncertainties, and actual results may differ from those projected. Additional details about the transactions can be found in the Form 4 filings with the SEC. Cosmos Health has not provided any further comment on the potential impact of these share purchases on the company’s operations or market performance.
In other recent news, Cosmos Health Inc. has secured a substantial contract manufacturing agreement with Pharmex S.A. to produce 300,000 bottles annually of the antiseptic drug AMBITASOL 1L over a five-year period. This development follows the upgrade of its Athens facility, which is now certified by the European Medicines Agency. In another strategic move, Cosmos Health has entered the Albanian market by launching its Sky Premium Life food supplements brand in partnership with Pharma Cell, securing an initial order valued at $300,000. Meanwhile, the company has postponed its planned securities offering as it prepares to file its Annual Report for the fiscal year ending December 31, 2024. Cosmos Health is also advancing its weight management product, CCX0722, towards clinical trials, with the market launch anticipated in the first half of 2026. Furthermore, the company has filed two new patent applications for cancer treatments targeting glioma and hematologic malignancies, underscoring its collaboration with Cloudpharm and the National Hellenic Research Foundation. These recent developments highlight Cosmos Health’s strategic efforts to expand its product offerings and enhance its global presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.